Search results for "Differentiation therapy"

showing 6 items of 6 documents

Retinoic Acid affects Lung Adenocarcinoma growth by inducing differentiation via GATA6 activation and EGFR and Wnt inhibition

2016

AbstractA fundamental task in cancer research aims at the identification of new pharmacological therapies that can affect tumor growth. Differentiation therapy might exploit this function not only for hematological diseases, such as acute promyelocytic leukemia (APML) but also for epithelial tumors, including lung cancer. Here we show that Retinoic Acid (RA) arrests in vitro and in vivo the growth of Tyrosine Kinase Inhibitors (TKI) resistant Non Small Cell Lung Cancer (NSCLC). In particular, we found that RA induces G0/G1 cell cycle arrest in TKI resistant NSCLC cells and activates terminal differentiation programs by modulating the expression of GATA6, a key transcription factor involved …

0301 basic medicineAcute promyelocytic leukemiaScienceEGFRRetinoic acidMice NudeTretinoinBiologyArticle03 medical and health scienceschemistry.chemical_compoundDifferentiation therapySettore BIO/13 - Biologia ApplicataCarcinoma Non-Small-Cell LungCell Line TumorGATA6 Transcription FactormedicineRetinoic acidAnimalsHumansLung cancerProtein Kinase InhibitorsWnt Signaling PathwayTranscription factorCell ProliferationMultidisciplinaryQRWnt signaling pathwayCell Differentiationmedicine.diseaseG1 Phase Cell Cycle CheckpointsXenograft Model Antitumor Assaysrespiratory tract diseasesErbB Receptorslung cancerAnimals; Carcinoma Non-Small-Cell Lung; Cell Differentiation; Cell Line Tumor; Cell Proliferation; Drug Resistance Neoplasm; ErbB Receptors; G1 Phase Cell Cycle Checkpoints; GATA6 Transcription Factor; Humans; Mice Nude; Protein Kinase Inhibitors; Signal Transduction; Tretinoin; Wnt Signaling Pathway; Xenograft Model Antitumor Assays030104 developmental biologychemistryDrug Resistance NeoplasmImmunologyCancer researchMedicineAdenocarcinomaEngineering sciences. TechnologyTyrosine kinaseSignal Transduction
researchProduct

AMG900 as novel inhibitor of the translationally controlled tumor protein

2020

Abstract Introduction Cancer is one of the leading causes of death worldwide. Classical cytotoxic chemotherapy exerts high side effects and low tumor selectivity. Translationally controlled tumor protein (TCTP) is a target for differentiation therapy, a promising, new therapeutic approach, which is expected to be more selective and less toxic than cytotoxic chemotherapy. The aim of the present investigation was to identify novel TCTP inhibitors. Methods We performed in silico screening and molecular docking using a chemical library of more than 31,000 compounds to identify a novel inhibitor of TCTP. We tested AMG900 in vitro for binding to TCTP by microscale thermophoresis and co-immunoprec…

0301 basic medicineApoptosisCell Cycle ProteinsToxicologyResting Phase Cell CycleFlow cytometry03 medical and health sciences0302 clinical medicineCyclin D1Differentiation therapyCell Line TumorNeoplasmsTranslationally-controlled tumor proteinBiomarkers TumormedicineHumansCyclin D3medicine.diagnostic_testbiologyChemistryG1 PhaseTumor Protein Translationally-Controlled 1General MedicineMolecular Docking SimulationBlot030104 developmental biologyProtein Biosynthesis030220 oncology & carcinogenesisCancer cellMCF-7 CellsCancer researchbiology.proteinPhthalazinesCyclin-dependent kinase 6Chemico-Biological Interactions
researchProduct

Role of TCTP for Cellular Differentiation and Cancer Therapy

2017

The translationally controlled tumor protein (TCTP) is a highly conserved protein that is regulated due to a high number of extracellular stimuli. TCTP has an important role for cell cycle and normal development. On the other side, tumor reversion and malignant transformation have been associated with TCTP. TCTP has been found among the 12 genes that are differentially expressed during mouse oocyte maturation, and an overexpression of this gene was reported in a wide variety of different cancer types. Its antiapoptotic effect is indicated by the interaction with several proapoptotic proteins of the Bcl-2 family and the p53 tumor suppressor protein. In this article, we draw attention to the …

0301 basic medicineCell growthCellular differentiationCancerBiologyCell cyclemedicine.diseaseMalignant transformation03 medical and health sciences030104 developmental biology0302 clinical medicineDifferentiation therapy030220 oncology & carcinogenesisCancer cellTranslationally-controlled tumor proteinmedicineCancer research
researchProduct

Genome-wide miRNA profiling and pivotal roles of miRs 125a-5p and 17-92 cluster in human neutrophil maturation and differentiation of acute myeloid l…

2019

19 p.-7 fig.-1 tab.

0301 basic medicineMyeloidCellular differentiationCD34miR-125a-5pBiology03 medical and health sciences0302 clinical medicineNeutrophil differentiationDifferentiation therapyneutrophil differentiationmedicinehumanmiRNANeutrophil differentiationmiR-17-92Myeloid leukemiamedicine.diseaseCell biologyLeukemia030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisStem cellResearch PaperHumanOncotarget
researchProduct

Meeting Report: The 11th International Conference on Differentiation Therapy and Innovative Therapeutics in Oncology

2007

The International Conference on Differentiation Therapy group of clinicians and researchers has met for more than 20 years and the most recent meeting in 2005 was held in Shanghai, China ( [1][1]). This group fostered the required networks to translate these novel strategies to clinical practice, as

Clinical PracticeCancer Researchmedicine.medical_specialtyPathologyOncologyDifferentiation therapybusiness.industryFamily medicineeducationmedicineAlternative medicinebusinessCancer Research
researchProduct

Meeting the Challenge of Targeting Cancer Stem Cells

2019

Notwithstanding cancer patients benefit from a plethora of therapeutic alternatives, drug resistance remains a critical hurdle. Indeed, the high mortality rate is associated with metastatic disease, which is mostly incurable due to the refractoriness of metastatic cells to current treatments. Increasing data demonstrate that tumors contain a small subpopulation of cancer stem cells (CSCs) able to establish primary tumor and metastasis. CSCs are endowed with multiple treatment resistance capabilities comprising a highly efficient DNA damage repair machinery, the activation of survival pathways, enhanced cellular plasticity, immune evasion and the adaptation to a hostile microenvironment. Due…

cancer stem cells0301 basic medicinecancer stem cellPhysiologymedicine.medical_treatmentPopulationReviewMetastasis03 medical and health sciencesepigenetic inhibitor0302 clinical medicineDifferentiation therapyCancer stem cellepigenetic inhibitorsmedicineanti-cancer therapiesmetastasisEpigeneticseducationlcsh:QH301-705.5education.field_of_studybusiness.industryanti-cancer therapieCancerCell BiologyImmunotherapymedicine.diseasePrimary tumor030104 developmental biologylcsh:Biology (General)030220 oncology & carcinogenesisCancer researchimmunotherapybusinessDevelopmental BiologyFrontiers in Cell and Developmental Biology
researchProduct